Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Investig Dermatol Symp Proc ; 12(1): 48-9, 2007 May.
Article in English | MEDLINE | ID: mdl-17502870

ABSTRACT

Etanercept (Amgen Inc, Thousand Oaks, CA) is a human soluble p75 tumor necrosis factor (TNF) receptor-human-IgG1 (hup75 TNFR-huIgG1) fusion protein used in the treatment of chronic inflammatory diseases in humans, including rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. To be able to study the effects of the soluble receptor fusion protein in mouse models, including those that mimic human granulomatous infections, a murine soluble p75-TNF receptor-murine IgG1 (murine p75-murine IgG1) fusion protein had to be constructed. This article discusses the generation, large-scale production, and purification of this molecule.


Subject(s)
Immunoglobulin G/biosynthesis , Immunoglobulin G/isolation & purification , Receptors, Tumor Necrosis Factor/biosynthesis , Receptors, Tumor Necrosis Factor/isolation & purification , Animals , Etanercept , Humans , Mice , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/isolation & purification , Species Specificity
2.
J Investig Dermatol Symp Proc ; 12(1): 50-1, 2007 May.
Article in English | MEDLINE | ID: mdl-17502871

ABSTRACT

Overproduction of inflammatory mediators, such as tumor necrosis factor (TNF), is key to the development and maintenance of inflammatory processes. Etanercept is a soluble TNF receptor fusion protein used in the treatment of various chronic inflammatory diseases, including rheumatoid arthritis and psoriasis. This study investigated the effects of murine p75-Fc, a soluble TNF receptor protein, on TNF-induced IL-6 production in mice. Six groups of mice received either murine p75-Fc (0.15, 0.50, 1.5, 5, and 15 mg/kg) or phosphate-buffered saline. Three days later, mice were injected intravenously with 10 microg of murine TNF and blood samples were taken after 3 hours. Serum IL-6 and TNF were measured by ELISA. Mice treated with 5 and 15 mg/kg murine p75-Fc demonstrated complete inhibition of TNF-induced IL-6 production. Murine p75-Fc (1.5 mg/kg) resulted in a partial but significant reduction of TNF-induced IL-6 production. No TNF was detected in 5 and 15 mg/kg murine p75-Fc-treated mice, except one in the 5 mg/kg dose group. In conclusion, murine p75-Fc completely inhibits TNF-induced IL-6 production in mice.


Subject(s)
Immunoglobulin G/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Etanercept , Humans , Interleukin-6/biosynthesis , Mice , Mice, Inbred BALB C , Receptors, Tumor Necrosis Factor , Recombinant Fusion Proteins/pharmacology , Tumor Necrosis Factor-alpha/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL